Transthyretin amyloid cardiomyopathy Treatment Market

Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.

Transthyretin amyloid cardiomyopathy Treatment Market contains market size and forecasts of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment in Global, including the following market information:

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Transthyretin Stabilizers Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment include Pfizer Inc, GlaxoSmithKline Plc, Eidos Therapeutics, Ionis Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Prothena Corporation Plc, Intellia Therapeutics, Inc and Corino Therapeutics, Inc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Segment Percentages, by Type, 2021 (%)

Transthyretin Stabilizers

Nonsteroidal Anti-inflammatory Drugs (NSAID)

RNAi Therapy

Others

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Segment Percentages, by Application, 2021 (%)

Hereditary Transthyretin Amyloidosis (hATTR)

Wild Type Transthyretin Amyloidosis (wtATTR)

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer Inc

GlaxoSmithKline Plc

Eidos Therapeutics

Ionis Pharmaceuticals, Inc

Alnylam Pharmaceuticals

Prothena Corporation Plc

Intellia Therapeutics, Inc

Corino Therapeutics, Inc